Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Zosano Pharma Corp (NASDAQ:ZSAN) is looking at strategic alternatives and reduced 31% of its staff as the FDA rejected its already-rejected migraine drug last month.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- M207, known as Qtrypta, includes a new delivery system for migraine drug triptan zolmitriptan. But Zosano's resubmission did not show a "complete response to the deficiencies" outlined in the agency's 2020 rejection.
- The company had 29 R&D employees at the end of 2021. Now, it has 21, according to Zosano's latest 10-K filing.
- But even if the company can get the drug approved, it will likely face more hurdles, according to the SEC filing.
- Related: Zosano Pharma Announces Publication Of Early Data On Influenza Vaccine.
- As of December 31, 2021, Zosano held cash and cash equivalents of $11.0 million.
- Price Action: ZSAN shares are down 3.36% at $0.19 during the market session on the last check Friday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.